Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis

PLoS One. 2014 May 22;9(5):e97917. doi: 10.1371/journal.pone.0097917. eCollection 2014.

Abstract

Background: Hypertension is common after acute stroke onset. Previous studies showed controversial effects of early blood pressure (BP) lowering on stroke outcomes. The aim of this study is to assess the effects of early BP lowering on early and long-term outcomes after acute stroke.

Methods: A meta-analysis was conducted with prospective randomized controlled trials assessing the effects of early BP lowering on early and long-term outcomes after acute stroke compared with placebo. Literature searching was performed in the databases from inception to December 2013. New evidence from recent trials were included. Outcomes were analyzed as early (within 30 days) and long-term (from 3 to 12 months) endpoints using summary estimates of relative risks (RR) and their 95% confidence intervals (CI) with the fixed-effect model or random-effect model.

Results: Seventeen trials providing data from 13236 patients were included. Pooled results showed that early BP lowering after acute stroke onset was associated with more death within 30 days compared with placebo (RR: 1.34 and 95% CI: 1.02, 1.74, p = 0.03). However the results showed that early BP lowering had no evident effect on early neurological deterioration, early death within 7 days, long-term death, early and long-term dependency, early and long-term combination of death or dependency, long-term stroke recurrence, long-term myocardial infarction and long-term CVE.

Conclusions: The new results lend no support to early BP lowering after acute stroke. Early BP lowering may increase death within 30 days after acute stroke.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Humans
  • Hypertension / physiopathology
  • Hypertension / therapy*
  • Placebos
  • Stroke / mortality
  • Stroke / physiopathology*

Substances

  • Placebos

Grants and funding

This work was supported by the sub-program of “12-5” National Science & Technique Support Program of China (2011BAI08B11 to YP), National Natural Science Foundation of China (NSFC 30973479, 31070953 to YP) and Science & Technique Plan fund of Guangdong Province (2009B060700040 to YP), and also supported in part by NSFC (No. 30600164 and No. 81072242 to YT), the Natural Science Foundation of Guangdong Province (No. S2011010004708 to YT), the Fundamental Research Funds for the Central Universities and Funds for Pearl River Science & Technology Star of Guangzhou City to YT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.